Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acura names new COO
Mr Jones is currently vice president, strategy and business analysis at Adolor, a specialty pharmaceutical company focused on developing and commercializing pain management products. Mr Jones received his
Mr Jones is currently vice president, strategy and business analysis at Adolor, a specialty pharmaceutical company focused on developing and commercializing pain management products. Mr Jones received his
This trial is a randomized, double-blinded, placebo-controlled study which will enroll up to 450 patients at approximately 25 sites in the US. In connection with this study, Corcept
The single-center study, which NuRx expects to complete in the fourth quarter of 2008, is designed to evaluate the safety and tolerability of the compound. NRX4204 is the
Of the $6.4 million purchase amount, $5.85 million was paid at the time of closing and the remaining proceeds are expected within the next six weeks. The company
With an initial focus on an influenza virus vaccine, the collaboration will determine if the combination of ImmuneRegen’s vaccine adjuvant compound, Viprovex, and DelSite’s unique adjuvant system, based
Under the terms of the five-year agreement, Akorn will be responsible for the exclusive manufacturing and supply of three OTC eye care products. The line of products will
The randomized, double-blind, placebo-controlled Phase III clinical trial will enroll approximately 450 patients with postherpetic neuralgia (PHN). Patients will be randomized into two treatment groups: 1800mg Gabapentin GR
This decision follows a favorable opinion from the Orphan Drugs Committee of the European Medicines Evaluation Agency (EMEA). The orphan drug status granted by the EMEA facilitates the
The trial met a key endpoint, demonstrating a clinically relevant adjuvant effect when the Iomai patch was used with a single dose of the 45-microgram H5N1 vaccine. The
Trident’s unique parameter driven plus custom pluggable design promises to deliver a new era of needed scalability, productivity, and ease-of-use to the global clinical IVRS market. Ed Tourtellotte,